Absence of a scalp-specific cancer excess challenges the UV-exposure hypothesis and supports maintaining standard, individualized skin cancer risk assessment rather than AA-specific screening ...
ImmunityBio, Inc. receives a Strong Buy rating, driven by ANKTIVA's compelling clinical data and major regulatory catalysts ...
The rapid clinical validation of mRNA technology during the COVID‑19 pandemic has powerfully accelerated its application in ...
Anaveon, a late-stage preclinical biotechnology company focused on reprogramming the immune system for the treatment of autoimmune and inflammatory diseases, today announced that new clinical data ...
Earlier this month, a cluster of severe acute respiratory illnesses aboard the Dutch-flagged cruise ship MV Hondius was reported to the World Health Organization (WHO). The infections have since been ...
Multidimensional analyses demonstrate that repeated DeltEx DRI dosing preserves immune function, drives tumor microenvironment remodeling, and correlates with improved survival ou ...
Five issued U.S. patents cover the combination of ImmunityBio’s IL-15 receptor agonist (NAI) with Bacillus Calmette-Guérin ...
Orphan Drug Designation confers regulatory, financial and strategic advantagesEO2463 has shown potentially disease modifying activity in clinical ...
Biopsy and next-generation sequencing identified an HSV 1 variant causing ulcerative esophagitis and ileitis in a healthy 26 ...
Analysis demonstrates a lower cost per sustained responder and cystectomy avoided with ANKTIVA plus BCG compared to TAR-200 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results